- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Zanubrutinib Plus Venetoclax Yields High Response Rates in Treatment-Naive CLL/SLL
May 31st 2025, 10:00pm
Zanubrutinib in combination with venetoclax was highly active in patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Dr Picozzi on the Addition of TTFields to Gemcitabine and Nab-Paclitaxel in Locally Advanced PDAC
May 31st 2025, 9:42pm
Vincent Picozzi, MD, discusses the addition of TFields to gemcitabine and nab-paclitaxel in locally advanced pancreatic ductal adenocarcinoma.
Imlunestrant With/Without Abemaciclib Generates Improved PROs in ER+/HER2– Advanced Breast Cancer
May 31st 2025, 9:30pm
Patient-reported outcomes revealed that imulunestrant with or without abemaciclib was favored vs SOC in ER-positive, HER2-negative breast cancer.
Luspatercept Increases Likelihood of Lasting Transfusion Independence in ESA-Naive, Lower-Risk MDS
May 31st 2025, 9:29pm
Durable improvements in transfusion independence and an early indication of potential OS benefit were seen with luspatercept in extended follow-up.
Adding Zilovertamab Vedotin to Standard Care Shows Strong ORR for DLBCL
May 31st 2025, 8:19pm
Zilovertamab vedotin plus R-GemOx elicits responses in patients with relapsed or refractory diffuse large B-cell lymphoma.
MK-1084 Yields Responses With Manageable Safety in KRAS G12C+ CRC
May 31st 2025, 7:54pm
MK-1084 produced responses and was safe in KRAS G12C–mutated advanced colorectal cancer.
Dr Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC
May 31st 2025, 7:26pm
Raffaele Califano, MD, discusses molecularly stratified outcomes amivantamab with chemotherapy vs chemotherapy alone in patients with advanced EGFR-mutant NSCLC.
Dr Chahoud on Early Efficacy With Zanzalintinib Plus Nivolumab With/Without Relatlimab in ccRCC
May 31st 2025, 7:17pm
Jad Chahoud, MD, MPH, MHA, shares early-phase data with zanzalintinib plus nivolumab with or without relatlimab-rmbw in previously untreated ccRCC.
Long-Term Data Underscore Role of Zanubrutinib in Treatment-Naive CLL/SLL With 17p Deletions
May 31st 2025, 6:24pm
Zanubrutinib retained long-term efficacy as a frontline treatment in CLL/SLL harboring 17p deletions.
Sotorasib/Panitumumab Resistance May Be Linked to Genomic Alterations in KRAS G12C+ mCRC
May 31st 2025, 4:20pm
Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.
Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC
May 31st 2025, 3:15pm
Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.
Frontline Anlotinib Plus CapeOX Elicits Similar Efficacy to SOC Therapy in RAS/BRAF Wild-Type mCRC
May 31st 2025, 2:41pm
Anlotinib/chemotherapy demonstrated similar responses and PFS outcomes vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type mCRC.
ctDNA-Guided Chemo Does Not Yield RFS Benefit in Stage III Colon Cancer
May 31st 2025, 2:20pm
Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.
T-DXd Represents a New SOC in Second-Line HER2+ Gastric/GEJ Cancer
May 31st 2025, 12:00pm
T-DXd demonstrated clinically meaningful antitumor responses as second-line treatment in HER2-positive gastric/GEJ cancer.
Vepdegestrant Improves PFS in ESR1-Mutant ER+/HER2– Advanced Breast Cancer
May 31st 2025, 12:00pm
PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.
ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC
May 31st 2025, 12:00pm
Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.
Adjuvant Chemotherapy Improves DFS in Molecularly Higher-Risk NSCLC
May 31st 2025, 12:00pm
Adjuvant chemotherapy generated a DFS benefit over observation in patients identified as having higher-risk nonsquamous NSCLC per a prognostic assay.
KITE-363 Elicits Responses With Acceptable Tolerability in R/R B-Cell Lymphoma
May 30th 2025, 11:42pm
Phase 1 data indicate that KITE-363 represents a promising therapeutic approach for patients with relapsed/refractory B-cell lymphoma.
T-DXd Rechallenge Is Safe After Grade 1 ILD in Breast Cancer and Other Solid Tumors
May 30th 2025, 11:25pm
A high rate of patients with breast cancer and other solid tumors were rechallenged with trastuzumab deruxtecan after grade 1 interstitial lung disease.
Dr Strickler on the Efficacy of Sotorasib Plus Panitumumab/Chemo in KRAS G12C+ mCRC
May 30th 2025, 11:11pm
John H. Strickler, MD, discusses the preliminary efficacy of sotorasib in combination with multiple agents across tumor types harboring KRAS G12C mutations.